DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice

Vaccine

Volumn 21, Issue 31, 2003, Pages 4609-4615

  Kamachi, Kazunari ^a   Konda, Toshifumi ^a   Arakawa, Yoshichika ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

DNA vaccine; Pertussis; Pertussis toxin

Indexed keywords

ACELLULAR VACCINE; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; EXPERIMENTAL INFECTION; EXPRESSION VECTOR; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; LEUKOCYTOSIS; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERTUSSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TOXIN STRUCTURE;

EID: 0142169002     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00441-9     Document Type: Article

References (43)

1. Robinson A., Irons L.I., Ashworth L.A. Pertussis vaccine: present status and future prospects. Vaccine. 3:1985;11-22.
2. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine: ad hoc group for the study of pertussis vaccines. Lancet. 9091:1997;1569-1577.
3. Blumberg D.A., Lewis K., Mink C.M., Christenson P.D., Chatfield P., Cherry J.D. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics. 91:1993;1158-1165.
4. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 8369:1984;122-126.
5. Donnelly S., Loscher C.E., Lynch M.A., Mills K.H.G. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1β in a new murine model for analysis of neuronal side effects of vaccination. Infect. Immun. 69:2001;4217-4223.
6. Greco D., Salmaso S., Mastrantonio P.et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:1996;341-348.
7. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:1996;349-355.
8. Tamura M., Nogimori K., Murai S.et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry. 21:1982;5516-5522.
9. Katada K., Ui M. Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc. Natl. Acad. Sci. U.S.A. 79:1982;3129-3133.
10. Bigio M., Rossi R., Nucci D., Borri M.G.et al. Monoclonal antibodies against pertussis toxin subunits. FEMS Microbiol. Lett. 51:1988;7-12.
11. Sato H., Ito A., Sato Y. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect. Immun. 46:1984;422-428.
12. Sato H., Sato Y. Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect. Immun. 58:1990;3369-3374.
13. Lee S.F., March R.J., Halperin S.A., Faulkner G., Gao L. Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii. Infect. Immun. 67:1999;1511-1516.
14. Nascimento I.P., Dias W.O., Mazzantini R.P.et al. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect. Immun. 68:2000;4877-4883.
15. Askelöf P., Rodmalm K., Wrangsell G.et al. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. Proc. Natl. Acad. Sci. U.S.A. 87:1990;1347-1351.
16. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15:1997;617-648.
17. Mielcarek N., Cornette J., Schacht A.M.et al. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect. Immun. 65:1997;544-550.
18. Barry E.M., Gomez-Duarte O., Chatfield S.et al. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect. Immun. 64:1996;4172-4181.
19. Boucher P., Sato H., Sato Y., Locht C. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Infect. Immun. 62:1994;449-456.
20. Aberle J.H., Aberle S.W., Allison S.L.et al. A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J. Immunol. 163:1999;6756-6761.
21. Deliyannis G., Boyle J.S., Brady J.L., Brown L.E., Lew A.M. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge. Proc. Natl. Acad. Sci. U.S.A. 97:2000;6676-6680.
22. Riedl P., Kholy S.E., Reimann J., Schirmbeck R. Priming biologically active antibody responses against an isolated, conformational viral epitope by DNA vaccination. J. Immunol. 169:2002;1251-1260.
23. Feng C.G., Palendira U., Demangel C., Spratt J.M., Malin A.S., Britton W.J. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis. Infect. Immun. 69:2001;4174-4176.
24. Tanghe A., Content J., van Vooren J.P., Portaels F., Huygen K. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect. Immun. 69:2001;5403-5411.
25. Tanghe A., D'souza S., Rosseels V.et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect. Immun. 69:2001;3041-3047.
26. Da'dara A.A., Skelly P.J., Fatakdawala M., Visovatti S., Eriksson E., Harn D.A. Comparative efficacy of the Schistosoma mansoni nucleic acid vaccine, Sm23, following microseeding or gene gun delivery. Parasite Immunol. 24:2002;179-187.
27. Gurunathan S., Sacks D.L., Brown D.R.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1997;1137-1147.
28. Horner A.A., Van Uden J.H., Zubeldia J.M., Broide D., Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol. Rev. 179:2001;102-118.
29. Lee Y.L., Ye Y.L., Yu C.I.et al. Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum. Gene Ther. 12:2001;2065-2079.
30. Thirdborough S.M., Radcliffe J.N., Friedmann P.S., Stevenson F.K. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell Lymphoma. Cancer Res. 62:2002;1757-1760.
31. Zöller M., Christ O. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination. J. Immunol. 166:2001;3440-3450.
32. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
33. Williams R.S., Johnston S.A., Riedy M., DeVit M.J., McElligott S.G., Sanford J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc. Natl. Acad. Sci. U.S.A. 88:1991;2726-2730.
34. Weiss R., Scheiblhofer S., Freund J., Ferreira F., Livey I., Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine. 20:2002;3148-3154.
35. Mills K.H., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:1993;399-410.
36. Peppoloni S., Nencioni L., Di Tommaso A.et al. Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infect. Immun. 59:1991;3768-3773.
37. Ryan M., Murphy G., Gothefors L., Nilsson L., Storsaeter J., Mills K.H. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J. Infect. Dis. 175:1997;1246-1250.
38. Fry N.K., Neal S., Harrison T.G., Miller E., Matthews R., George R.C. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in The United Kingdom. Infect. Immun. 69:2001;5220-5228.
39. Gzyl A., Augustynwicz E., Van Loo I., Slusarczyk J. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine. 20:2002;299-303.
40. Mooi F.R., He Q., Van Oirschot H., Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect. Immun. 67:1999;3133-3134.
41. Mooi F.R., Van Oirschot H., Heuvelman K., Van Der Heide H.G.J., Gaastra W., Willems R.J.L. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66:1998;670-675.
42. Castro M.G., McNamara U., Carbonetti N.H. Expression, activity and cytotoxicity of pertussis toxin S1 subunit in transfected mammalian cells. Cell. Microbiol. 3:2001;45-54.
43. Pizza M., Covacci A., Bartoloni A.et al. Mutants of pertussis toxin suitable for vaccine development. Science. 246:1989;497-500.